Iovance Biotherapeutics is trading 4.17% lower at $14.01 as markets weakened on October 22; available reporting showed no clear company-specific catalyst. - Reuters reported pressure on growth stocks and weaker Nasdaq futures amid renewed concerns about AI spending and rising oil prices. - Shares had rallied on October 19 and 20, and reporting described profit-taking after a recent surge. - The decline may reflect both that pullback and the broader risk-off session, rather than a newly announced company event.